|
|
Volumn 22, Issue 1, 2016, Pages 8-10
|
|
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZACITIDINE;
DECITABINE;
ENTINOSTAT;
HISTONE DEACETYLASE INHIBITOR;
IMMUNOMODULATING AGENT;
IPILIMUMAB;
NIVOLUMAB;
PEMBROLIZUMAB;
ANTINEOPLASTIC AGENT;
BENZAMIDE DERIVATIVE;
MONOCLONAL ANTIBODY;
PYRIDINE DERIVATIVE;
CANCER CELL;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
COLON CANCER;
COLORECTAL CANCER;
DRUG SAFETY;
EPIGENETICS;
HUMAN;
LUNG CANCER;
MELANOMA;
MYELODYSPLASTIC SYNDROME;
NEOPLASM;
NONHUMAN;
NOTE;
OVARY CANCER;
PRIORITY JOURNAL;
SOLID TUMOR;
T CELL LYMPHOMA;
TRANSLATIONAL RESEARCH;
TREATMENT OUTCOME;
ART;
CARCINOMA, NON-SMALL-CELL LUNG;
GENETIC EPIGENESIS;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
PROCEDURES;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AZACITIDINE;
BENZAMIDES;
CARCINOMA, NON-SMALL-CELL LUNG;
EPIGENESIS, GENETIC;
HUMANS;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
PYRIDINES;
|
|
EID: 84954212865
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0116-8 Document Type: Note |
|
Times cited : (51)
|
|
References (0)
|
